These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 18425967

  • 1. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.
    Cochrane Database Syst Rev; 2008 Apr 16; 2008(2):CD006739. PubMed ID: 18425967
    [Abstract] [Full Text] [Related]

  • 2. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.
    Vasc Health Risk Manag; 2008 Apr 16; 4(4):753-68. PubMed ID: 19065993
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B, Sonne DP, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2017 May 10; 5(5):CD012204. PubMed ID: 28489279
    [Abstract] [Full Text] [Related]

  • 5. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N.
    Expert Opin Investig Drugs; 2008 Jun 10; 17(6):845-53. PubMed ID: 18491986
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Jun 10; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.
    Clin Drug Investig; 2011 Jun 10; 31(9):665-74. PubMed ID: 21819162
    [Abstract] [Full Text] [Related]

  • 11. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR, Barbieri M, Marfella R, Paolisso G.
    Diabetes Care; 2012 Oct 10; 35(10):2076-82. PubMed ID: 22688551
    [Abstract] [Full Text] [Related]

  • 12. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.
    Ned Tijdschr Geneeskd; 2010 Oct 10; 154():A886. PubMed ID: 20298625
    [Abstract] [Full Text] [Related]

  • 13. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr 10; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH, Hussien AK, Omran AAE, Elsayed AA, Saeed H.
    Clin Exp Pharmacol Physiol; 2021 Dec 10; 48(12):1589-1602. PubMed ID: 34333803
    [Abstract] [Full Text] [Related]

  • 15. DPP-4 inhibitors in clinical practice.
    Palalau AI, Tahrani AA, Piya MK, Barnett AH.
    Postgrad Med; 2009 Nov 10; 121(6):70-100. PubMed ID: 19940419
    [Abstract] [Full Text] [Related]

  • 16. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.
    Diabetes Metab; 2012 Oct 10; 38(4):359-66. PubMed ID: 22809630
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X, Men P, Wang Y, Zhai S, Liu G.
    Lipids Health Dis; 2016 Nov 23; 15(1):204. PubMed ID: 27881129
    [Abstract] [Full Text] [Related]

  • 19. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N.
    Br J Pharmacol; 2013 Jul 23; 169(5):1048-57. PubMed ID: 23488656
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug 23; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.